# Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

> **NCT02938585** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 68 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** turoctocog alfa
- **DRUG:** turoctocog alfa

## Key facts

- **NCT ID:** NCT02938585
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-12
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-12-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938585, "Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02938585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*